Skip to main content
Supplement ScienceSupplementScience

I3C (Indole-3-Carbinol) Research & Evidence

·

This content is for informational purposes only and does not constitute medical advice. Statements about dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary — consult your healthcare provider before starting any supplement. Full disclaimer

Evidence Level

Moderate

I3C has been studied for estrogen metabolism modulation since the early 1990s. Bradlow et al. first demonstrated its ability to shift estrogen metabolism toward 2-hydroxylation. A notable pilot study by Bell et al. (2000) in Gynecologic Oncology showed 50% regression of CIN 2-3 at 200-400mg daily over 12 weeks. However, the variable metabolite profile created during gastric acid conversion has led many practitioners to recommend DIM as a more predictable alternative.

Evidence by Condition

ConditionStudied DoseEvidence
Estrogen metabolism200-400mg dailyModerate
Cervical dysplasia support200-400mg dailyEmerging
General detoxification200mg dailyPreliminary
Full I3C (Indole-3-Carbinol) Guide

References

  1. RCTBell MC, Crowley-Nowick P, Bradlow HL, Sepkovic DW, Schmidt-Grimminger D, Howell P, Mayeaux EJ, Tucker A, Turbat-Herrera EA, Mathis JM (2000). Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecologic Oncology. DOI PubMed
  2. RCTReed GA, Arneson DW, Putnam WC, Smith HJ, Gray JC, Sullivan DK, Mayo MS, Crowell JA, Hurwitz A (2005). Single-dose and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3,3'-diindolylmethane. Cancer Epidemiology, Biomarkers & Prevention. DOI PubMed